Literature DB >> 12119480

Calcium and phosphate plasma levels in dialysis patients after dietary Ca-P overload. Role of gastric acid secretion.

Giorgio Graziani1, Salvatore Badalamenti, Giovanna Como, Maurizio Gallieni, Silvia Finazzi, Claudio Angelini, Diego Brancaccio, Claudio Ponticelli.   

Abstract

In normal subjects, the gastric ionisation of calcium and phosphate seems to be a prerequisite for their intestinal absorption. We investigated the behavior of the plasma calcium and phosphate profile in 30 patients on regular dialysis treatment in the 6 h following a meal containing 1 g of calcium and 2 g of phosphate. Moreover, to assess the role of gastric acidity, the study was repeated after 3 days on omeprazole administration, to nearly abolish gastric acid secretion. Both total plasma calcium and ionized calcium peaked after the meal (at 30 and 120 min, respectively) only in basal study, while no peak was observed after the administration of omeprazole. Surprisingly, both in basal and in the omeprazole study the levels of plasma phosphate did not increase after the test meal. In conclusion, as in normal subjects, the gastric ionization of dietary calcium promotes the intestinal absorption of calcium in uremic patients on dialysis treatment, while the acute gastric acid inhibition by omeprazole reduced the intestinal calcium transport. In contrast, with the "trade off" hypothesis we did not observe any postprandial phosphate peak after the dietary load, and, in contrast with normal subjects, omeprazole administration did not influence the phosphate profile. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12119480     DOI: 10.1159/000064290

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  16 in total

1.  Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative.

Authors:  Shelly L Gray; Andrea Z LaCroix; Joseph Larson; John Robbins; Jane A Cauley; JoAnn E Manson; Zhao Chen
Journal:  Arch Intern Med       Date:  2010-05-10

2.  The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos).

Authors:  Laura E Targownik; William D Leslie; K Shawn Davison; David Goltzman; Sophie A Jamal; Nancy Kreiger; Robert G Josse; Stephanie M Kaiser; Christopher S Kovacs; Jerilynn C Prior; Wei Zhou
Journal:  Am J Gastroenterol       Date:  2012-07-10       Impact factor: 10.864

3.  Hip fracture risk in patients with a diagnosis of pernicious anemia.

Authors:  Nathan A Merriman; Mary E Putt; David C Metz; Yu-Xiao Yang
Journal:  Gastroenterology       Date:  2009-12-21       Impact factor: 22.682

Review 4.  The role of the gastrointestinal tract in calcium homeostasis and bone remodeling.

Authors:  J Keller; T Schinke
Journal:  Osteoporos Int       Date:  2013-03-28       Impact factor: 4.507

5.  Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients.

Authors:  Douglas A Corley; Ai Kubo; Wei Zhao; Charles Quesenberry
Journal:  Gastroenterology       Date:  2010-03-27       Impact factor: 22.682

Review 6.  Chronic proton pump inihibitor therapy and calcium metabolism.

Authors:  Yu-Xiao Yang
Journal:  Curr Gastroenterol Rep       Date:  2012-12

Review 7.  Proton pump inhibitors and fracture risk: true effect or residual confounding?

Authors:  Michael Bodmer; Christian Meier; Marius E Kraenzlin; Christoph R Meier
Journal:  Drug Saf       Date:  2010-10-01       Impact factor: 5.606

8.  Acid-suppressive medications and risk of bone loss and fracture in older adults.

Authors:  Elaine W Yu; Terri Blackwell; Kristine E Ensrud; Teresa A Hillier; Nancy E Lane; Eric Orwoll; Douglas C Bauer
Journal:  Calcif Tissue Int       Date:  2008-09-24       Impact factor: 4.333

9.  Bone density in proton pump inhibitors users: a prospective study.

Authors:  Kamil Ozdil; Resul Kahraman; Abdurrahman Sahin; Turan Calhan; Erdem H Gozden; Umit Akyuz; Burak Erer; Mehmet H Sokmen
Journal:  Rheumatol Int       Date:  2013-03-02       Impact factor: 2.631

10.  Proton pump inhibitors and risk of vitamin and mineral deficiency: evidence and clinical implications.

Authors:  Joel J Heidelbaugh
Journal:  Ther Adv Drug Saf       Date:  2013-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.